EHRA EUROPACE 2013 - European Society of Cardiology
EHRA EUROPACE 2013 - European Society of Cardiology
EHRA EUROPACE 2013 - European Society of Cardiology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
INDEX<br />
SeSSIonS by CATegory - name/Page number<br />
Translational<br />
New types antiarrhythmic drugs for atrial fibrillation................................................................................................................................................................................................................................................................. 38<br />
Scientific Projects <strong>of</strong> new e-<strong>Cardiology</strong> nucleus members ............................................................................................................................................................................................................................................ 37<br />
State <strong>of</strong> the art lecture: cardiac resynchronisation therapy ........................................................................................................................................................................................................................................... 63<br />
Translational session on Brugada’s syndrome.............................................................................................................................................................................................................................................................................................. 80<br />
Multimodality imaging <strong>of</strong> cardiac arrhythmias ............................................................................................................................................................................................................................................................................................ 82<br />
The grey areas in genetic syndromes ........................................................................................................................................................................................................................................................................................................................... 126<br />
Systemic effects <strong>of</strong> atrial fibrillation .................................................................................................................................................................................................................................................................................................................................. 129<br />
Thoracoscopic ablation <strong>of</strong> longstanding persistent AF – bail out in failed catheter ablation or as primary procedure? ................. 171<br />
From deciphering molecular pathogenesis to developing targeted new therapies ...................................................................................................................................................... 174<br />
Ablation <strong>of</strong> complex fractionated atrial electrogrammes .................................................................................................................................................................................................................................................. 175<br />
Moderated Posters<br />
New challenges in cardiac pacing .......................................................................................................................................................................................................................................................................................................................................... 51<br />
ICD therapy: current issues and future strategies.............................................................................................................................................................................................................................................................................. 91<br />
J-wave syndromes and arrhythmia complication after TAVI ........................................................................................................................................................................................................................................ 100<br />
Hot topics in genetics and anticoagulation ........................................................................................................................................................................................................................................................................................................ 137<br />
Catheter ablation .................................................................................................................................................................................................................................................................................................................................................................................................... 153<br />
Atrial fibrillation.......................................................................................................................................................................................................................................................................................................................................................................................................... 181<br />
Poster Session<br />
Poster session Sunday 8:30 to Monday 18:00............................................................................................................................................................................................................................................................................................. 25<br />
On behalf <strong>of</strong> the ESC Working Group on Cardiac Cellular Electrophysiology<br />
Poster session 1 ......................................................................................................................................................................................................................................................................................................................................................................................................... 52<br />
Poster session 2 ......................................................................................................................................................................................................................................................................................................................................................................................................... 92<br />
Poster session 3 ......................................................................................................................................................................................................................................................................................................................................................................................................... 101<br />
Poster session 4 ......................................................................................................................................................................................................................................................................................................................................................................................................... 138<br />
Poster session 5 ......................................................................................................................................................................................................................................................................................................................................................................................................... 155<br />
Poster session 6 ......................................................................................................................................................................................................................................................................................................................................................................................................... 183<br />
Satellite Symposium<br />
ICD therapy: patient selection, device technology and clinical results .................................................................................................................................................................................................... 44<br />
Innovations in the diagnosis and treatment <strong>of</strong> cardiac arrhythmias .............................................................................................................................................................................................................. 44<br />
Will percutaneous mitral valve repair impact your management <strong>of</strong> patients with mitral regurgitation? ......................................................................... 77<br />
AF: a riddle wrapped in a mystery inside an enigma? .................................................................................................................................................................................................................................................................. 76<br />
Home Monitoring <strong>of</strong> cardiac devices: clinic efficiencies and improved patient outcomes ............................................................................................................................. 75<br />
Left atrial appendage closure for risk reduction <strong>of</strong> AF related stroke: what every electrophysiologist should know.......................... 75<br />
Reducing stroke risk: early AF detection and new anticoagulants ................................................................................................................................................................................................................... 74<br />
Fresh perspectives on hemodynamic ambulatory optimisation in CRT .............................................................................................................................................................................................. 77<br />
Manage every lead - From implantation to extraction ............................................................................................................................................................................................................................................................ 76<br />
Improved patient and economic outcomes with advanced HF solutions ........................................................................................................................................................................................ 73<br />
Novel oral anticoagulants for stroke prevention in atrial fibrillation: understanding our way forward .............................................................................. 73<br />
CRT Care Pathway: from patient selection to clinical outcome.......................................................................................................................................................................................................................... 87<br />
Status quo: antithrombotic management in atrial fibrillation...................................................................................................................................................................................................................................... 87<br />
AF ablation: transforming complexity into safe, effective and efficient .................................................................................................................................................................................................. 121<br />
Changing paradigms in electrophysiological arrhythmia treatment............................................................................................................................................................................................................... 121<br />
A new paradigm in ICD therapy: clinical perspectives on a novel single-chamber ICD system with complete ............................................ 122<br />
atrial diagnostics<br />
Benefits <strong>of</strong> sleep apnea screening in the management <strong>of</strong> atrial fibrillation patients .................................................................................................................................................... 124<br />
Ground breaking new therapies for electrophysiologists .................................................................................................................................................................................................................................................. 123<br />
New opportunities and new challenges <strong>of</strong> anticoagulation in atrial fibrillation ..................................................................................................................................................................... 124<br />
Novel oral anticoagulants during clinical procedures in patients with AF: translating promising data into real-life practice .............. 122<br />
Advances in ablation catheter technology and role <strong>of</strong> contact force......................................................................................................................................................................................................... 123<br />
202
Change language